Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats

Izzettin Hatip-Al-Khatib, Katsunori Iwasaki, Yoshitaka Yoshimitsu, Takashi Arai, Nobuaki Egashira, Kenichi Mishima, Tomoaki Ikeda, Michihiro Fujiwara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetrahydro-1 H-1-benzazepin-8-yl) propan-1-one fumarate)) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment. In this study, the effects of TAK-147 at 2 mg kg -1 p.o. for 21 days, compared to donepezil (E2020), on the levels of ACh, catecolamines and indoleamines were investigated in the ventral hippocampus (VH) of freely moving rats by microdialysis-high-performance liquid chromatography. The results revealed that the VH contains 92.05±21.97 fmol 20 μl -1 ACh and the following monoamines levels (pg 30 μl -1), norepinephrine (NE) 1.92±0.39, epinephrine (Epi) 1.91±0.183, 3-methoxy-4- hydroxyphenylglycol (MHPG) 11.53±3.22, normetanephrine 3.26±0.61, dopamine (DA) 0.77±0.23, 3,4-dihydroxyphenylacetic acid (DOPAC) 3.37±1.01, homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid; HVA) 4.04±0.93, 3-methoxytyramine 0.64±0.13, serotonin (5-HT) 0.73±0.16 and 5-hydroxyindoleacetic acid (5-HIAA) 313.15±18.42. On the 21st day and prior to the last dose, TAK-147 increased ACh, Epi, DA and 5-HT, whereas E2020 increased MHPG, Epi and DA. Following the last dose, TAK-147 increased NE, whereas E2020 increased NE, ACh and 5-HT in addition to their effects prior to the last dose. TAK-147 decreased HVA:DA ratio, but only marginally decreased DOPAC:DA and 5-HIAA:5-HT ratios. On the other hand, E2020 decreased ratios of HVA:DA, DOPAC:DA (prior to the last dose), and 5-HIAA:5-HT (90-180 min after the last dose). Both drugs decreased MHPG:NE only at 180 min after the last dose. The results also showed that TAK-147 increased Epi:NE ratio prior to and for 120 min following the last dose, whereas E2020 increased the ratio only before the last dose. The present results show that TAK-147 at a subthreshold dose could differentially increase ACh and 5-HT, compared to MHPG increased by E2020. The last dose of each drug could extend their effects to other monoamines. The increase of the monoamines levels, in addition to that on the ACh, and decrease of their oxidation could be of value in the treatment of the AD, other dementic diseases and the cohort neurological disorders depending on the type of the monoamine underlying the disorder.

Original languageEnglish
Pages (from-to)1035-1044
Number of pages10
JournalBritish Journal of Pharmacology
Volume145
Issue number8
DOIs
Publication statusPublished - Dec 1 2005
Externally publishedYes

Fingerprint

Acetylcholine
Oral Administration
Hippocampus
Dopamine
Serotonin
Norepinephrine
Epinephrine
Hydroxyindoleacetic Acid
Homovanillic Acid
Alzheimer Disease
Normetanephrine
Pharmaceutical Preparations
3,4-Dihydroxyphenylacetic Acid
Fumarates
Acids
Microdialysis
Esterases
donepezil
TAK 147
Nervous System Diseases

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. / Hatip-Al-Khatib, Izzettin; Iwasaki, Katsunori; Yoshimitsu, Yoshitaka; Arai, Takashi; Egashira, Nobuaki; Mishima, Kenichi; Ikeda, Tomoaki; Fujiwara, Michihiro.

In: British Journal of Pharmacology, Vol. 145, No. 8, 01.12.2005, p. 1035-1044.

Research output: Contribution to journalArticle

Hatip-Al-Khatib, Izzettin ; Iwasaki, Katsunori ; Yoshimitsu, Yoshitaka ; Arai, Takashi ; Egashira, Nobuaki ; Mishima, Kenichi ; Ikeda, Tomoaki ; Fujiwara, Michihiro. / Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. In: British Journal of Pharmacology. 2005 ; Vol. 145, No. 8. pp. 1035-1044.
@article{f357367e13c34b11b5de69bc801d0d16,
title = "Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats",
abstract = "Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetrahydro-1 H-1-benzazepin-8-yl) propan-1-one fumarate)) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment. In this study, the effects of TAK-147 at 2 mg kg -1 p.o. for 21 days, compared to donepezil (E2020), on the levels of ACh, catecolamines and indoleamines were investigated in the ventral hippocampus (VH) of freely moving rats by microdialysis-high-performance liquid chromatography. The results revealed that the VH contains 92.05±21.97 fmol 20 μl -1 ACh and the following monoamines levels (pg 30 μl -1), norepinephrine (NE) 1.92±0.39, epinephrine (Epi) 1.91±0.183, 3-methoxy-4- hydroxyphenylglycol (MHPG) 11.53±3.22, normetanephrine 3.26±0.61, dopamine (DA) 0.77±0.23, 3,4-dihydroxyphenylacetic acid (DOPAC) 3.37±1.01, homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid; HVA) 4.04±0.93, 3-methoxytyramine 0.64±0.13, serotonin (5-HT) 0.73±0.16 and 5-hydroxyindoleacetic acid (5-HIAA) 313.15±18.42. On the 21st day and prior to the last dose, TAK-147 increased ACh, Epi, DA and 5-HT, whereas E2020 increased MHPG, Epi and DA. Following the last dose, TAK-147 increased NE, whereas E2020 increased NE, ACh and 5-HT in addition to their effects prior to the last dose. TAK-147 decreased HVA:DA ratio, but only marginally decreased DOPAC:DA and 5-HIAA:5-HT ratios. On the other hand, E2020 decreased ratios of HVA:DA, DOPAC:DA (prior to the last dose), and 5-HIAA:5-HT (90-180 min after the last dose). Both drugs decreased MHPG:NE only at 180 min after the last dose. The results also showed that TAK-147 increased Epi:NE ratio prior to and for 120 min following the last dose, whereas E2020 increased the ratio only before the last dose. The present results show that TAK-147 at a subthreshold dose could differentially increase ACh and 5-HT, compared to MHPG increased by E2020. The last dose of each drug could extend their effects to other monoamines. The increase of the monoamines levels, in addition to that on the ACh, and decrease of their oxidation could be of value in the treatment of the AD, other dementic diseases and the cohort neurological disorders depending on the type of the monoamine underlying the disorder.",
author = "Izzettin Hatip-Al-Khatib and Katsunori Iwasaki and Yoshitaka Yoshimitsu and Takashi Arai and Nobuaki Egashira and Kenichi Mishima and Tomoaki Ikeda and Michihiro Fujiwara",
year = "2005",
month = "12",
day = "1",
doi = "10.1038/sj.bjp.0706288",
language = "English",
volume = "145",
pages = "1035--1044",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats

AU - Hatip-Al-Khatib, Izzettin

AU - Iwasaki, Katsunori

AU - Yoshimitsu, Yoshitaka

AU - Arai, Takashi

AU - Egashira, Nobuaki

AU - Mishima, Kenichi

AU - Ikeda, Tomoaki

AU - Fujiwara, Michihiro

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetrahydro-1 H-1-benzazepin-8-yl) propan-1-one fumarate)) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment. In this study, the effects of TAK-147 at 2 mg kg -1 p.o. for 21 days, compared to donepezil (E2020), on the levels of ACh, catecolamines and indoleamines were investigated in the ventral hippocampus (VH) of freely moving rats by microdialysis-high-performance liquid chromatography. The results revealed that the VH contains 92.05±21.97 fmol 20 μl -1 ACh and the following monoamines levels (pg 30 μl -1), norepinephrine (NE) 1.92±0.39, epinephrine (Epi) 1.91±0.183, 3-methoxy-4- hydroxyphenylglycol (MHPG) 11.53±3.22, normetanephrine 3.26±0.61, dopamine (DA) 0.77±0.23, 3,4-dihydroxyphenylacetic acid (DOPAC) 3.37±1.01, homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid; HVA) 4.04±0.93, 3-methoxytyramine 0.64±0.13, serotonin (5-HT) 0.73±0.16 and 5-hydroxyindoleacetic acid (5-HIAA) 313.15±18.42. On the 21st day and prior to the last dose, TAK-147 increased ACh, Epi, DA and 5-HT, whereas E2020 increased MHPG, Epi and DA. Following the last dose, TAK-147 increased NE, whereas E2020 increased NE, ACh and 5-HT in addition to their effects prior to the last dose. TAK-147 decreased HVA:DA ratio, but only marginally decreased DOPAC:DA and 5-HIAA:5-HT ratios. On the other hand, E2020 decreased ratios of HVA:DA, DOPAC:DA (prior to the last dose), and 5-HIAA:5-HT (90-180 min after the last dose). Both drugs decreased MHPG:NE only at 180 min after the last dose. The results also showed that TAK-147 increased Epi:NE ratio prior to and for 120 min following the last dose, whereas E2020 increased the ratio only before the last dose. The present results show that TAK-147 at a subthreshold dose could differentially increase ACh and 5-HT, compared to MHPG increased by E2020. The last dose of each drug could extend their effects to other monoamines. The increase of the monoamines levels, in addition to that on the ACh, and decrease of their oxidation could be of value in the treatment of the AD, other dementic diseases and the cohort neurological disorders depending on the type of the monoamine underlying the disorder.

AB - Zanapezil (TAK-147 (3-[1benzylpiperdin-4-yl]-1-(2,3,4,5-tetrahydro-1 H-1-benzazepin-8-yl) propan-1-one fumarate)) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment. In this study, the effects of TAK-147 at 2 mg kg -1 p.o. for 21 days, compared to donepezil (E2020), on the levels of ACh, catecolamines and indoleamines were investigated in the ventral hippocampus (VH) of freely moving rats by microdialysis-high-performance liquid chromatography. The results revealed that the VH contains 92.05±21.97 fmol 20 μl -1 ACh and the following monoamines levels (pg 30 μl -1), norepinephrine (NE) 1.92±0.39, epinephrine (Epi) 1.91±0.183, 3-methoxy-4- hydroxyphenylglycol (MHPG) 11.53±3.22, normetanephrine 3.26±0.61, dopamine (DA) 0.77±0.23, 3,4-dihydroxyphenylacetic acid (DOPAC) 3.37±1.01, homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid; HVA) 4.04±0.93, 3-methoxytyramine 0.64±0.13, serotonin (5-HT) 0.73±0.16 and 5-hydroxyindoleacetic acid (5-HIAA) 313.15±18.42. On the 21st day and prior to the last dose, TAK-147 increased ACh, Epi, DA and 5-HT, whereas E2020 increased MHPG, Epi and DA. Following the last dose, TAK-147 increased NE, whereas E2020 increased NE, ACh and 5-HT in addition to their effects prior to the last dose. TAK-147 decreased HVA:DA ratio, but only marginally decreased DOPAC:DA and 5-HIAA:5-HT ratios. On the other hand, E2020 decreased ratios of HVA:DA, DOPAC:DA (prior to the last dose), and 5-HIAA:5-HT (90-180 min after the last dose). Both drugs decreased MHPG:NE only at 180 min after the last dose. The results also showed that TAK-147 increased Epi:NE ratio prior to and for 120 min following the last dose, whereas E2020 increased the ratio only before the last dose. The present results show that TAK-147 at a subthreshold dose could differentially increase ACh and 5-HT, compared to MHPG increased by E2020. The last dose of each drug could extend their effects to other monoamines. The increase of the monoamines levels, in addition to that on the ACh, and decrease of their oxidation could be of value in the treatment of the AD, other dementic diseases and the cohort neurological disorders depending on the type of the monoamine underlying the disorder.

UR - http://www.scopus.com/inward/record.url?scp=30544452029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30544452029&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0706288

DO - 10.1038/sj.bjp.0706288

M3 - Article

C2 - 15951830

AN - SCOPUS:30544452029

VL - 145

SP - 1035

EP - 1044

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -